Nasdaq · CIK 0001374690
LRMR Larimar Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 11 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Signals
Open-market buys and sells at Larimar Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | James E Flynn director, owner, other buy | $30M 9,375,000 shares | +152% | - |
Transactions
The last 17 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 29, 2026 | John B. Harlow Jr. President and COO | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 50,000 | 11 d ago |
| Sep 29, 2026 | John B. Harlow Jr. President and COO | AGrant or award Stock Option (Right to Buy)derivative | +800,000 | $0.00 | $0 | 800,000 | 11 d ago |
| Jul 31, 2025 | James E Flynn director, owner, other | POpen-market purchase Common Stockindirect: Through Deerfield Private Design Fund III, L.P. | +3,387,529 | $3.20 | $11M | 9,538,918 | Aug 4, 2025 |
| Jul 31, 2025 | James E Flynn director, owner, other | POpen-market purchase Common Stockindirect: Through Deerfield Private Design Fund IV, L.P. | +3,387,539 | $3.20 | $11M | 9,538,945 | Aug 4, 2025 |
| Jul 31, 2025 | James E Flynn director, owner, other | POpen-market purchase Common Stockindirect: Through Deerfield Healthcare Innovations Fund, L.P. | +2,599,932 | $3.20 | $8.3M | 7,321,129 | Aug 4, 2025 |
| May 13, 2025 | James E Flynn director, owner, other | AGrant or award Stock Option (Right to Buy)derivativeindirect: Through Deerfield Management Company, L.P. | +19,000 | $0.00 | $0 | 19,000 | May 15, 2025 |
| May 13, 2025 | Frank E Thomas director | AGrant or award Stock Option (Right to Buy)derivative | +19,000 | $0.00 | $0 | 19,000 | May 14, 2025 |
| May 13, 2025 | Jeffrey W Sherman director | AGrant or award Stock Option (Right to Buy)derivative | +19,000 | $0.00 | $0 | 19,000 | May 14, 2025 |
| May 13, 2025 | Joseph Truitt director | AGrant or award Stock Option (Right to Buy)derivative | +19,000 | $0.00 | $0 | 19,000 | May 14, 2025 |
| May 13, 2025 | Jonathan S Leff director | AGrant or award Stock Option (Right to Buy)derivative | +19,000 | $0.00 | $0 | 19,000 | May 14, 2025 |
| May 13, 2025 | Thomas Edward Hamilton director | AGrant or award Stock Option (Right to Buy)derivative | +19,000 | $0.00 | $0 | 19,000 | May 14, 2025 |
| Jan 22, 2025 | Carole Ben-Maimon President and CEO | AGrant or award Common Stock | +91,000 | $0.00 | $0 | 387,208 | Jan 24, 2025 |
| Jan 22, 2025 | Michael Celano Chief Financial Officer | AGrant or award Common Stock | +34,185 | $0.00 | $0 | 178,181 | Jan 24, 2025 |
| Jan 22, 2025 | Russell Clayton Chief Medical Officer | AGrant or award Common Stock | +23,306 | $0.00 | $0 | 45,806 | Jan 24, 2025 |
| Jan 22, 2025 | Michael Celano Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +205,111 | $0.00 | $0 | 205,111 | Jan 24, 2025 |
| Jan 22, 2025 | Russell Clayton Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +139,838 | $0.00 | $0 | 139,838 | Jan 24, 2025 |
| Jan 22, 2025 | Carole Ben-Maimon President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +546,000 | $0.00 | $0 | 546,000 | Jan 24, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Carole Ben-MaimonPresident and CEO
- Michael CelanoChief Financial Officer
- Russell ClaytonChief Medical Officer
- James E Flynnowner, director, other
- Thomas Edward Hamiltondirector
- John B. Harlow Jr.President and COO
- Jonathan S Leffdirector
- Jeffrey W Shermandirector
- Frank E Thomasdirector
- Joseph Truittdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.